Background And Aims: The present prospective, randomised study was done to evaluate induction characteristics with bispectral (BIS) index guided infusion of propofol and etomidate.
Materials And Methods: After institutional ethical committee approval, 70 patients, aged 18-60 years, American Society of Anaesthesiologists (ASA) I and II scheduled for elective surgery were included. Patients were randomly allocated into one of the two groups. In Group E, patients received etomidate infusion at a rate of 0.07 mg kg min and in Group P, received propofol infusion of 0.7 mg kg min. Time from start of infusion to loss of palpebral reflex (T), loss of verbal command (T), BIS to reach 50 (T), mean induction dose and incremental dose of each drug required to keep BIS, haemodynamic parameters and adverse effects like pain, myoclonus, apnoea and postoperative nausea and vomiting (PONV) were also noted.
Results: TT, and T was faster in E as compared to group and was statistically significant for all parameters. Mean induction dose of drug required till BIS 50 was 2.68 ± 0.56 mg kg and 0.242 ± 0.11 mg kg in group and E, respectively. There was a significant difference between the groups with group E requiring incremental dose in a significant proportion of patients ( = 0.004). There was a significant decrease in MAP in group as compared to E. In group P, more number of patients experienced pain and had apnoea episode as compared to group E. ( < 0.001). Myoclonus was observed in group E only ( = 0.016).
Conclusion: BIS-guided titration of propofol and etomidate infusion for induction did not result in reduction of the dose, haemodynamic variations and other effects.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7641050 | PMC |
http://dx.doi.org/10.4103/ija.IJA_221_20 | DOI Listing |
Korean J Anesthesiol
January 2025
Department of Anaesthesiology and Pain Medicine, Samsung Medical Centre, Sungkyukwan University School of Medicine, Seoul, Republic of Korea.
Background: Remimazolam is a novel ultra-short-acting benzodiazepine known for its hemodynamic stability over propofol. However, its hemodynamic effects compared to those of etomidate are not well established. This study aimed to determine whether the use of remimazolam is non-inferior to etomidate with regard to the occurrence of post-induction hypotension in patients undergoing coronary arterial bypass grafting.
View Article and Find Full Text PDFEndocrine
December 2024
Department of Internal Medicine, Endocrinology and Diabetes, Medical University of Warsaw, Warsaw, Poland.
Purpose: Severe Cushing's syndrome (SCS) is a life-threatening endocrine condition that requires prompt medical intervention. Intravenous etomidate infusion is considered to be the most effective in rapid cortisol overproduction inhibition. This single-center retrospective study aimed to present the safety and effectiveness of intravenous, low-dose, lipid-formulated etomidate infusion in patients with SCS.
View Article and Find Full Text PDFBioorg Chem
January 2025
Jiangsu Key Laboratory of Marine Pharmaceutical Compound Screening, School of Pharmacy, Jiangsu Ocean University, Lianyungang 222005, China. Electronic address:
Intravenous anesthetics play a crucial role during surgery. Etomidate, a commonly used intravenous anesthetic agent, is prized for its rapid onset and smooth induction of anesthesia. However, it has a pronounced adverse effect on adrenal function suppression.
View Article and Find Full Text PDFCrit Care Med
November 2024
Department of Medicine, Division of Emergency Medicine, McMaster University, Hamilton, ON, Canada.
Objectives: To compare the safety and efficacy of ketamine and etomidate as induction agents to facilitate emergent endotracheal intubation.
Data Sources: We searched MEDLINE, Embase, Cochrane Clinical Trials Register, and ClinicalTrials.gov from inception to April 3, 2024.
Psychopharmacology (Berl)
November 2024
Office of China National Narcotics Control Commission, China Pharmaceutical University Joint Laboratory on Key Technologies of Narcotics Control, Beijing, China, 100193.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!